enhertu triple negative breast cancer

Release time ：Dec-28,2024

Enhertu is a targeted therapy for triple-negative breast cancer (TNBC), functioning as a HER2-directed antibody-drug conjugate that aims to deliver chemotherapeutic agents precisely to HER2-positive cancer cells. Typically, TNBC does not respond to HER2-targeted treatments, but Enhertu offers a novel therapeutic option for certain patients through its distinct mechanism of action.

Clinical trials have demonstrated significant efficacy of Enhertu against specific subtypes of TNBC. It works by binding to the HER2 protein on cancer cell surfaces and internalizing the attached chemotherapy drugs, thereby eliminating the cancer cells. This targeted approach may reduce harm to healthy cells and potentially decrease some side effects associated with conventional chemotherapy. However, it's important to recognize that not all TNBC patients are candidates for Enhertu, and treatment outcomes can vary among individuals.

For patients diagnosed with TNBC, obtaining professional medical advice is essential. Physicians will tailor a treatment plan based on the patient's specific condition, tumor characteristics, and overall health. Patients must adhere strictly to the physician's instructions when using Enhertu or any medication, refraining from self-medicating or altering dosages. Regular follow-ups and monitoring are crucial for evaluating treatment efficacy and detecting potential side effects.